Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.15 HKD | -3.49% | +12.78% | -18.23% |
30/04 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
29/04 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.23% | 1.47B | |
+5.66% | 111B | |
+11.23% | 105B | |
-0.38% | 21.93B | |
-12.15% | 22.34B | |
-7.66% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug